Psilocybin therapy is an emerging form of psychotherapy that has been gaining attention in recent years. It involves the use of psilocybin, a psychedelic compound found in certain mushrooms, to treat mental health issues such as depression, anxiety, and addiction. While it may seem like a modern development, psilocybin therapy has been around for decades. This article will take a look at the history of psilocybin therapy from its beginnings in the 1950s to its current status today. 

The 1950s and 1960s

The first recorded use of psilocybin was by Swiss chemist Albert Hofmann in 1958. He isolated the compound from a species of mushroom known as Psilocybe mexicana. Shortly after his discovery, researchers began to explore its potential therapeutic uses. In 1962, Timothy Leary and Richard Alpert (later known as Ram Dass) conducted experiments on volunteers at Harvard University using psilocybin to study spiritual experiences. They concluded that there were potential benefits for treating psychological disorders with the drug. ^[1]

The 1970s and 1980s

During the 1970s, the exploration of psilocybin was active prior to the imposition of strict regulations due to the war on drugs. This decade was marked by investigations into the psychopharmacological properties of psilocybin and its potential therapeutic use for a range of mental health conditions. A noteworthy study by Beug MW and Bigwood J in 1982 examined psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms, contributing valuable data to the body of knowledge about this psychedelic compound. ^[2]

Additionally, psychiatrist Stanislav Grof was a prominent figure in this era, utilizing substances such as psilocybin and LSD in his exploration of the therapeutic potential of altered states of consciousness. His work, while regarded as somewhat controversial, established an important foundation in the field of psychedelic therapy.

The 1990s 

Research on the therapeutic benefits of psychedelics such as psilocybin was hampered in the 1990s due to an increase in restrictions on these substances by federal law enforcement agencies. Nevertheless, several researchers persisted in investigating the potential benefits of psychedelics. A systematic review from this period indicated that studies on the potential therapeutic benefits of psychedelics, including psilocybin, had begun to accelerate despite these regulatory challenges.​ ^[3]​

One such researcher was psychiatrist Charles Grob who conducted clinical trials with cancer patients at Harbor-UCLA Medical Center. These patients were administered low doses of psilocybin to alleviate symptoms related to depression and anxiety stemming from their diagnosis. Grob's findings demonstrated promising evidence for the therapeutic use of psychedelics, thereby paving the way for future research when legal circumstances would permit more extensive studies on these substances. ^[4]

The 2000s  

The turn of the millennium ushered in a new era of psychedelic research. In 2006, the Multidisciplinary Association for Psychedelic Studies (MAPS) began conducting groundbreaking clinical trials on post-traumatic stress disorder (PTSD) patients using MDMA-assisted psychotherapy​. ^[5]​ These clinical trials not only demonstrated statistically significant improvements in PTSD symptoms but also ignited a renewed interest in researching other psychedelic compounds, such as LSD and psilocybin, for treatment-resistant mental health conditions such as depression and anxiety disorders.

In the same period, the FDA approved the resumption of psychedelic research, a decision that was met with a resurgence in the study of psilocybin. Researchers from Johns Hopkins University were the first in the United States to receive regulatory authority to resume psychedelic research with healthy volunteers. In 2006, they initiated a landmark study focusing on the safety and long-term benefits of a single dosage of psilocybin, marking a significant stride in the rebirth of psilocybin research.​ ^[6]​

Psilocybin Therapy Today 

Today there are multiple studies being conducted exploring the potential benefits of using psychedelics such as LSD or psilocybin therapeutically, including treating depression, anxiety disorders, addiction problems, and, more recently, even treating Alzheimer's disease symptoms. 

While much research still needs to be conducted to fully understand the potential benefits and risks of psilocybin, the ongoing studies on this compound and other psychedelics offer promising insights into their potential as effective treatments for mental health issues. With increasing support for further research and a shift in public perception, there is hope that we will soon be able to unlock the full potential of psilocybin in improving mental health.

‍